Osteal Therapeutics completed an oversubscribed $30 million Series B equity financing. Proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate VT-X7 for treatment of periprosthetic joint infection (PJI) and fund new research.
Following the successful completion of an open-label Phase II trial, the company recently commenced enrollment of APEX, a randomized controlled study of VT-X7 in patients with chronic periprosthetic infections of the hip or knee.
VT-X7 (vancomycin HCL and tobramycin sulfate for irrigation) is a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin and tobramycin, broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat chronic periprosthetic joint infection. VT-X7 is a seven-day therapy designed to address the unmet clinical need for a rapid, reliable treatment for these rare but challenging infections.
In a Phase II clinical trial, 100% of VT-X7 patients were treated and received a new permanent joint prosthesis in seven days with 93% remaining infection-free at one year.
The APEX randomized controlled trial compares VT-X7 compared to two-stage exchange arthroplasty, the current standard of care for treatment of chronic PJI. The FDA granted VT-X7 Orphan Drug, Fast Track and Qualified Infectious Disease Product designations.
Osteal Therapeutics completed an oversubscribed $30 million Series B equity financing. Proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate VT-X7 for treatment of periprosthetic joint infection (PJI) and fund new research.
Following the successful completion of...
Osteal Therapeutics completed an oversubscribed $30 million Series B equity financing. Proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate VT-X7 for treatment of periprosthetic joint infection (PJI) and fund new research.
Following the successful completion of an open-label Phase II trial, the company recently commenced enrollment of APEX, a randomized controlled study of VT-X7 in patients with chronic periprosthetic infections of the hip or knee.
VT-X7 (vancomycin HCL and tobramycin sulfate for irrigation) is a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin and tobramycin, broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat chronic periprosthetic joint infection. VT-X7 is a seven-day therapy designed to address the unmet clinical need for a rapid, reliable treatment for these rare but challenging infections.
In a Phase II clinical trial, 100% of VT-X7 patients were treated and received a new permanent joint prosthesis in seven days with 93% remaining infection-free at one year.
The APEX randomized controlled trial compares VT-X7 compared to two-stage exchange arthroplasty, the current standard of care for treatment of chronic PJI. The FDA granted VT-X7 Orphan Drug, Fast Track and Qualified Infectious Disease Product designations.
Copy to clipboard 
